Medicine and Dentistry
Case-Control Study
100%
Bladder Cancer
100%
Ranitidine
100%
Odds Ratio
71%
Cancer Risk
28%
General Medicine
28%
Proton-Pump Inhibitor
28%
Dimethylnitrosamine
28%
Primary Health Care
14%
Urinary System
14%
Logistic Regression Analysis
14%
Histamine H2 Receptor
14%
Carcinogen
14%
Comorbidity
14%
Pharmacology, Toxicology and Pharmaceutical Science
Case-Control Study
100%
Bladder Cancer
100%
Ranitidine
100%
Proton Pump Inhibitor
28%
N-Nitrosodimethylamine
28%
Receptor Agonist
14%
Carcinogen
14%
Comorbidity
14%
Biochemistry, Genetics and Molecular Biology
Case-Control Study
100%
Ranitidine
100%
Proton Pump
28%
Receptor Agonists
14%
Histamine H2 Receptor
14%
Comorbidity
14%